Therasense Inc
Theralink Technologies, Inc., a commercial-stage precision medicine and molecular data-generating company, engages in the development and commercialization of oncology products in the United States. The company offers patented phosphoprotein and protein biomarker platform, and laboratory developed test technology targets multiple areas of oncology and drug development. It also provides precision … Read more
Therasense Inc (THER) - Net Assets
Latest net assets as of December 2023: $-38.12 Million USD
Based on the latest financial reports, Therasense Inc (THER) has net assets worth $-38.12 Million USD as of December 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.85 Million) and total liabilities ($40.97 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-38.12 Million |
| % of Total Assets | -1337.48% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | -62011.09% |
| Growth Volatility | 98.87 |
Therasense Inc - Net Assets Trend (2007–2023)
This chart illustrates how Therasense Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Therasense Inc (2007–2023)
The table below shows the annual net assets of Therasense Inc from 2007 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-09-30 | $-38.12 Million | -902.76% |
| 2022-09-30 | $-3.80 Million | -95.39% |
| 2021-09-30 | $-1.95 Million | -214.95% |
| 2020-09-30 | $1.69 Million | +110.62% |
| 2019-09-30 | $-15.94 Million | -7.62% |
| 2018-09-30 | $-14.81 Million | -1691.48% |
| 2017-09-30 | $-826.63K | -248.84% |
| 2016-09-30 | $555.38K | +500.06% |
| 2014-09-30 | $-138.82K | -325.49% |
| 2013-09-30 | $61.56K | -74.91% |
| 2012-09-30 | $245.37K | -75.06% |
| 2011-09-30 | $984.00K | +2047.85% |
| 2010-09-30 | $-50.52K | -652.30% |
| 2009-09-30 | $-6.71K | +88.03% |
| 2008-09-30 | $-56.11K | -1000.80% |
| 2007-09-30 | $-5.10K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Therasense Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 9368264700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (September 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $615.15K | % |
| Other Components | $55.02 Million | % |
| Total Equity | $-38.12 Million | 100.00% |
Therasense Inc Competitors by Market Cap
The table below lists competitors of Therasense Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ALMIRALL (E2Z.SG)
STU:E2Z
|
$106.97K |
|
Eco Innovation Group Inc
PINK:ECOX
|
$107.01K |
|
VIVACON
BE:VIA
|
$107.02K |
|
Unieuro SpA
STU:1UI
|
$107.11K |
|
RAMSAY GENERALE (GD6.SG)
STU:GD6
|
$106.95K |
|
First Tidal Acquisition Corp.
V:AAA-P
|
$106.95K |
|
NORDIC SEMICONDUCTO
BE:N0S
|
$106.83K |
|
ENERGY RECOVERY
BE:5E2
|
$106.76K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Therasense Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from -3,801,055 to -38,115,561, a change of -34,314,506.
- Net loss of 30,907,505 reduced equity.
- Dividend payments of 26,301 reduced retained earnings.
- Other factors decreased equity by 3,380,700.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-30.91 Million | -81.09% |
| Dividends Paid | $26.30K | -0.07% |
| Other Changes | $-3.38 Million | -8.87% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Therasense Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-09-30 | $-17.76 | $0.00 | x |
| 2008-09-30 | $-195.50 | $0.00 | x |
| 2009-09-30 | $-11.42 | $0.00 | x |
| 2010-09-30 | $-85.91 | $0.00 | x |
| 2011-09-30 | $1645.48 | $0.00 | x |
| 2012-09-30 | $410.31 | $0.00 | x |
| 2013-09-30 | $102.95 | $0.00 | x |
| 2014-09-30 | $-4.26 | $0.00 | x |
| 2016-09-30 | $8.46 | $0.00 | x |
| 2017-09-30 | $-10.64 | $0.00 | x |
| 2018-09-30 | $-86.18 | $0.00 | x |
| 2019-09-30 | $-32.21 | $0.00 | x |
| 2020-09-30 | $0.00 | $0.00 | x |
| 2021-09-30 | $0.00 | $0.00 | x |
| 2022-09-30 | $0.00 | $0.00 | x |
| 2023-09-30 | $-0.01 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Therasense Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -5093.56%
- • Asset Turnover: 0.21x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-85.85%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 0.00% | 0.00% | 0.00x | 0.00x | $-50.38K |
| 2008 | 0.00% | 0.00% | 0.00x | 0.00x | $-59.80K |
| 2009 | 0.00% | 0.00% | 0.00x | 0.00x | $-53.29K |
| 2010 | 0.00% | 0.00% | 0.00x | 0.00x | $-53.15K |
| 2011 | -106.61% | -393.20% | 0.17x | 1.57x | $-1.15 Million |
| 2012 | -388.21% | -121.96% | 0.69x | 4.60x | $-977.08K |
| 2013 | -513.18% | -405.37% | 0.10x | 12.76x | $-322.09K |
| 2014 | 0.00% | -178692.52% | 0.00x | 0.00x | $-440.00K |
| 2016 | -178.33% | -1338372.97% | 0.00x | 1.31x | $-1.05 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.93 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-19.03 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-9.60 Million |
| 2020 | -187.32% | -1749.32% | 0.06x | 1.89x | $-3.34 Million |
| 2021 | 0.00% | -1106.15% | 0.31x | 0.00x | $-5.40 Million |
| 2022 | 0.00% | -2244.96% | 0.22x | 0.00x | $-12.37 Million |
| 2023 | 0.00% | -5093.56% | 0.21x | 0.00x | $-27.10 Million |
Industry Comparison
This section compares Therasense Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Therasense Inc (THER) | $-38.12 Million | 0.00% | N/A | $106.97K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |